TRACON Pharmaceuticals, Inc.

1mon ago, source: CNN

TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin ...

TRACON Pharma Stock (NASDAQ:TCON), Analyst Ratings, Price Targets, Predictions

2mon ago, source: Benzinga.com

TRACON Pharmaceuticals Inc has a consensus price target of $4.4, established from looking at the 10 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC ...

Buy Rating Reaffirmed for TRACON Pharmaceuticals Post-Reverse Split and Envafolimab Valuation Update

1mon ago, source: Business Insider

TRACON Pharmaceuticals (TCON) Company Description: TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases.

TRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Announces Reverse Stock Split

1mon ago, source: Finanznachrichten

SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development ...

TRACON Pharmaceuticals Inc TCON

18d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

TRACON Pharmaceuticals Inc.

26d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

TRACON Pharmaceuticals Inc (TCON)

1mon ago, source: Investing

Get an in-depth profile of TRACON Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.

TRACON Pharmaceuticals, Inc. (TCON)

16d ago, source: Yahoo Finance

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

TRACON Pharmaceuticals Inc (TCON)

15d ago, source: Investing

TRACON Pharmaceuticals (NASDAQ:TCON) held its third-quarter 2023 earnings call, with the main focus on the ongoing ENVASARC trial and potential licensing opportunities for its ...

TRACON Pharmaceuticals, Inc. (TCON)

18d ago, source: Yahoo Finance

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.